REEP Presentation 23msc02004 23msc02005 23msc02010

A FORMULATION FOR ANTICANCER ACTIVITY OF A
BYPRODUCT OF SAFFRON, THE FLOWER PETALS AND

METHOD THEREOF
Submitted by:
Bhakti Joshi (23Msc02004)
Pratiti patel (23Msc02010)
Manali Patel (23Msc02005)
M.Sc. Biotechnology,
Semester- II
School Of Science
Submitted To
DR. AKHILESH PRAJAPATI
Associate Professor – Biotechnology
GSFC University, Vadodara
INTRODUCTION:
• Hepatocellular carcinoma (HCC) is an aggressive tumour that accounts for about 80 -90% of
cancer-related mor tality worldwide.
• Despite many therapeutic options, poor sur vival, severe adverse eff ects, and poor
compliance are obser ved in patients.
• The saff ron stigma is globally famous as a main therapeutic component of the saff ron plant
and has proven anticancer potential by various researchers, besides its other medicinal
uses.
• The Saff ron petals are discarded during the har vest process, however many scientists have
proven anti-bacterial, anti-spasmodic, anti-tumour immunomodulator y, hepatoprotective,
anti-hyper tensive, anti-diabetic, and anti-oxidant activity proper ties of saff ron petals.
• Thus, this patent compares the eff ects of Saff ron petals with Saff ron stigma on the
hepatocellular carcinoma cell line.
Patent Details
• Offi ce – India
• Application Number – 202111035127
• Application Date - 04.08.2021
• Publication Number – 202111035127
• Publication Kind - A
• Publication Date - 03.03.2023
• Applicants - AMITY UNIVERSITY
• Inventors - Nidhi Sharma, Dr Mar yam

Sarwat, Professor Subhrajit Biswas
DESCRIPTION:
• This study investigated the potential of saff ron petals, a byproduct of saff ron
production, for liver cancer therapy. Saff ron petal extract (SPE) was compared to the
traditionally used saff ron stigma extract (SSE) for its anticancer eff ects on human
liver cancer cells (HepG2).
• The results demonstrated that SPE exhibited superior effi cacy in inhibiting cancer cell
viability compared to SSE, as evidenced by a lower IC50 value in the MT T assay.
• Fur thermore, SPE signifi cantly reduced cancer cell migration and induced apoptosis,
a form of programmed cell death, as indicated by increased Caspase-3 expression
and decreased Bcl-2 expression.
• These fi ndings suggest that SPE possesses promising anti-cancer proper ties and
could be a valuable therapeutic candidate for liver cancer, either alone or in
combination with established treatments.
EXPERIMENTS :
1. Cell Viability Assay (MT T Assay):
This assay measured the eff ect of SPE and SSE on the viability of liver cancer cells -
HepG2 cells.
Cells were treated with diff erent concentrations of SPE and SSE (800ug /ml,
1600ug /ml, and 3200ug /ml) for 24 hours.
The concentration that inhibited 50% of cell growth (IC50) was determined.
Results: Both SPE and SSE inhibited the viability of cancer cells in a dose-dependent
manner. SPE had a lower IC50 value (1057 ug /ml) compared to SSE (3964 ug /ml). This
indicates that SPE was more potent in killing cancer cells, requiring a lower dose to
achieve the same eff ect.
2. Migration Assay: This assay measured the ability of cancer cells to migrate.
A scratch was made in a monolayer of liver cancer cells.
The cells were then treated with SPE or lef t untreated.
Cell migration into the scratched area was measured af ter 24 hours.
Results: SPE signifi cantly reduced the migration of liver cancer cells compared to
untreated cells.
3 . Gene Expression Analysis: This experiment investigated how SPE aff ects genes
involved in cell death (apoptosis).
Liver cancer cells were treated with SPE for diff erent time durations (24, 48, and 72
hours).
The expression levels of two genes, Caspase-3 (promotes apoptosis) and Bcl-2 (inhibits
apoptosis), were measured.
Results: SPE treatment increased the expression of Caspase-3 over time. SPE
treatment decreased the expression of Bcl-2 over time. These fi ndings suggest that
SPE may induce apoptosis in liver cancer cells.
CONCLUSION :
• In conclusion, this invention presents a novel application for saff ron petals, a
historically discarded byproduct. The study demonstrates that a saff ron petal extract
(SPE) exhibits superior anticancer activity against human liver cancer cells (HepG2)
compared to traditionally used saff ron stigma extract (SSE).
• SPE displayed greater potency in inhibiting cell viability, as evidenced by a lower

IC50 value in the MT T assay. Additionally, SPE signifi cantly reduced cancer cell
migration and induced apoptosis, a programmed cell death pathway.
• These fi ndings suggest that SPE possesses promising therapeutic potential for liver
cancer.
• The utilization of a readily available byproduct for cancer treatment off ers a
signifi cant economic and environmental advantage.
THANK YOU!

REEP Presentation 23msc02004 23msc02005 23msc02010

Uploaded by

Copyright:

Available Formats

REEP Presentation 23msc02004 23msc02005 23msc02010

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

REEP Presentation 23msc02004 23msc02005 23msc02010

Uploaded by

Copyright:

Available Formats

A FORMULATION FOR ANTICANCER ACTIVITY OF A

BYPRODUCT OF SAFFRON, THE FLOWER PETALS AND

• Application Number – 202111035127

• Application Date - 04.08.2021

• Publication Number – 202111035127

• Publication Date - 03.03.2023

• Applicants - AMITY UNIVERSITY

• Inventors - Nidhi Sharma, Dr Mar yam

A scratch was made in a monolayer of liver cancer cells.

The cells were then treated with SPE or lef t untreated.

• SPE displayed greater potency in inhibiting cell viability, as evidenced by a lower

You might also like